Calquence Capsule, Gelatin Coated
Product Images NDC 0310-0512

6 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Calquence (NDC 0310-0512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical_structure (Chemical Structure)

Chemical_structure (Chemical Structure)
Chemical structure of Acalabrutinib, the active ingredient in CALQUENCE 100 mg capsules. The diagram shows the molecular arrangement including heterocyclic rings and functional groups characteristic of this kinase inhibitor drug.*
FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A Kaplan-Meier survival curve chart showing progression-free survival percentage over time in months for three treatment groups: CALQUENCE plus Obinutuzumab, CALQUENCE alone, and Chlorambucil plus Obinutuzumab. The chart includes censored data markers and a table listing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure_2 (Figure 2)

Figure_2 (Figure 2)
A survival curve chart comparing progression-free survival (%) over time in months between CALQUENCE and IR or BR treatments. The solid line represents CALQUENCE, showing higher progression-free survival rates over approximately 20 months, while the dashed line represents IR or BR with lower survival rates. The chart includes a 'Number At Risk' table below, indicating patient counts at various time points for both groups, and censoring marks on the curves.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
A Kaplan-Meier curve graph comparing progression-free survival percentages over 23 months between CALQUENCE and IR or BR treatment groups. The solid line represents CALQUENCE, showing higher progression-free survival rates than the dashed line for IR or BR. The graph includes a table of the number of patients at risk over time for each group and marks censored data points.*
FDA Label Image

Figure_5 (Figure 4)

Figure_5 (Figure 4)
Kaplan-Meier plot showing progression-free survival (%) over time in months for two treatment groups: CALQUENCE + Venetoclax (solid line) and FCR/BR (dashed line). The chart includes a table of subjects at risk at different time points from 0 to 57 months. A legend indicates censored data points marked with plus signs.*
FDA Label Image

Calquence 100 mg Bottle Label (Calquence 100 mg Bottle Label)

Calquence 100 mg Bottle Label (Calquence 100 mg Bottle Label)
CALQUENCE 100 mg capsules label showing the product name and active ingredient acalabrutinib. It displays the quantity of 60 capsules, marked Rx only. The label states it is manufactured for AstraZeneca Pharmaceuticals LP and includes manufacturing site details in Sweden and Switzerland. The AstraZeneca logo is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.